Get the Stockscreener App
1.13
6.61%
-0.08
After Hours:
1.18
0.05
+4.42%
Prelude Therapeutics Inc stock is traded at $1.13, with a volume of 183.06K.
It is down -6.61% in the last 24 hours and up +34.84% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$1.21
Open:
$1.2
24h Volume:
183.06K
Relative Volume:
1.02
Market Cap:
$63.96M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.6348
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
-8.13%
1M Performance:
+34.84%
6M Performance:
+62.31%
1Y Performance:
-76.60%
1-Day Range:
$1.10
$1.2386
1-Week Range:
$1.10
$1.26
52-Week Range:
$0.6101
$5.075
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.13 | 67.35M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Heatmap analysis for Prelude Therapeutics Incorporated and competitorsMarket Risk Analysis & Low Volatility Stock Suggestions - Newser
Visualizing Prelude Therapeutics Incorporated stock with heatmapsWeekly Risk Report & Free Risk Controlled Daily Trade Plans - Newser
Strategies to average down on Prelude Therapeutics IncorporatedJuly 2025 Earnings & Real-Time Sentiment Analysis - Newser
Can Prelude Therapeutics Incorporated hit a new high this monthFed Meeting & Fast Gain Stock Tips - Newser
Long term hold vs stop loss in Prelude Therapeutics IncorporatedQuarterly Profit Summary & Smart Money Movement Alerts - Newser
Will Prelude Therapeutics Incorporated see short term momentum2025 Market Sentiment & Daily Stock Trend Reports - Newser
Understanding Prelude Therapeutics Incorporated’s price movementTrade Performance Summary & Consistent Profit Focused Trading Strategies - Newser
Using data tools to time your Prelude Therapeutics Incorporated exit2025 Performance Recap & Real-Time Chart Breakout Alerts - Newser
What MACD signals say about Prelude Therapeutics Incorporated2025 Bull vs Bear & Verified Entry Point Signals - Newser
Prelude Therapeutics Incorporated stock volume spike explainedMarket Sentiment Report & Verified Swing Trading Watchlist - Newser
Is Prelude Therapeutics Incorporated showing signs of accumulationWeekly Market Outlook & Weekly High Return Stock Forecasts - Newser
Sentiment analysis tools applied to Prelude Therapeutics Incorporated2025 Winners & Losers & Long-Term Growth Plans - Newser
Combining price and volume data for Prelude Therapeutics Incorporated2025 Market Overview & Technical Pattern Based Signals - Newser
Advanced analytics toolkit walkthrough for Prelude Therapeutics IncorporatedMarket Trend Report & Weekly Market Pulse Alerts - Newser
Developing predictive dashboards with Prelude Therapeutics Incorporated dataQuarterly Market Review & Technical Confirmation Alerts - Newser
Is Prelude Therapeutics Incorporated stock entering bullish territory2025 Trade Ideas & Stepwise Trade Signal Implementation - Newser
Detecting price anomalies in Prelude Therapeutics Incorporated with AIJuly 2025 Recap & Entry Point Confirmation Signals - Newser
Will Prelude Therapeutics Incorporated continue its uptrend2025 Technical Overview & Low Drawdown Trading Strategies - Newser
Does Prelude Therapeutics Incorporated fit your quant trading model2025 Market WrapUp & Long-Term Capital Growth Strategies - Newser
Price action breakdown for Prelude Therapeutics IncorporatedDividend Hike & Intraday High Probability Alerts - Newser
Real time scanner hits for Prelude Therapeutics Incorporated explainedPortfolio Performance Summary & Free Fast Gain Swing Trade Alerts - Newser
Is Prelude Therapeutics Incorporated stock reversal real or fakeWeekly Trend Report & Fast Gain Stock Tips - Newser
Published on: 2025-09-11 05:01:05 - Newser
heatmap analysis for prelude therapeutics incorporated and competitorsRisk Management & Technical Pattern Alert System - Newser
Tools to monitor Prelude Therapeutics Incorporated recovery probabilityQuarterly Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Has Prelude Therapeutics Incorporated formed a bullish divergence2025 Winners & Losers & Technical Pattern Based Buy Signals - Newser
Is Prelude Therapeutics Incorporated still worth holding after the dipRecession Risk & Weekly Momentum Stock Picks - Newser
Market reaction to Prelude Therapeutics Incorporated’s recent news2025 Price Action Summary & AI Based Trade Execution Alerts - Newser
Quantitative breakdown of Prelude Therapeutics Incorporated recent move2025 Technical Overview & Smart Investment Allocation Tips - Newser
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):